Your support group participation might improve your life more than you realize. A recently published study shows that support groups improve meaningful health-related outcomes, such as self-care, pulmonary hypertension symptom management, medication adherence and understanding related medical procedures.
The FDA recently approved Tyvaso (treprostinil) Inhalation Solution to improve exercise ability for people who have PH associated with interstitial lung disease. Manufactured by United Therapeutics, Tyvaso is the first FDA-approved treatment for Group 3 PH.
Vineet Agrawal, M.D., Ph.D., is the 2020 recipient of the Pulmonary Hypertension Association’s Aldrighetti Research Award for Young Investigators. Dr. Agrawal is a physician-scientist and instructor of medicine at Vanderbilt University Medical Center.
A new article based Pulmonary Hypertension Association Registry (PHAR) data suggests body weight plays a complex, important role in pulmonary arterial hypertension (PAH). The article, which recently was published in the Annals of the American Thoracic Society, investigated the effects of patient weight on day-to-day activities.
Learn about the latest discoveries in pulmonary hypertension (PH) research. Join the Pulmonary Hypertension Association (PHA) at 3 p.m. EDT, Oct. 9 for “Advancements in PH Research.” Dr. Todd Bull will provide an update on the scientific discoveries and research that could lead to the next generation of PH therapies.
Does your employer have a matching gift program? If so, you can double your contribution to the Pulmonary Hypertension Association (PHA). Depending on the employer, you might be eligible to provide twice the support for the pulmonary hypertension (PH) community, whether you’re an employee, spouse of an employee or retiree.
Would you like to learn more about the process of developing new drugs to treat pulmonary hypertension (PH)? Check out the latest issue of the Pulmonary Hypertension Association’s (PHA’s) official journal, Advances in Pulmonary Hypertension, now available online.
Jason Boehme, M.D., received the 2019 PHA Robyn J. Barst, M.D. Pediatric PH Research & Mentoring Grant in honor of Jackson Wall, one of three Pulmonary Hypertension Association (PHA) research grants awarded last year. An assistant professor of pediatrics at the University of California, San Francisco, Boehme is studying “Pulmonary Vascular Smooth Muscle Metabolic
Researchers who study pulmonary hypertension (PH) can apply now to advance their research at the PHA 2020 International PH Conference and Scientific Sessions, which brings the PH community to Anaheim, California, to learn, connect and share a focus on a common “Vision for a Cure.” In addition, all attendees at PHA 2020 may take
Ke Yuan, Ph.D., received the 2019 PHA Aldrighetti Research Award for Young Investigators, with sponsorship support provided by Actelion Pharmaceuticals, U.S. The award, one of three Pulmonary Hypertension Association (PHA) research grants awarded last year, funds Yuan’s proposal, “SDF1 signaling: A Master Regulator of Mural Cell-Dependent Vascular Remodeling in PAH.” Yuan is an associate